You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Liver conditions
  5. Chronic liver disease

Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]

  • In development
  • Reference number: GID-TA11414
  • Expected publication date: TBC
  • Project information
  • Project documents
  • Consultation

On this page

  1. Draft guidance
  2. Declaration of interests
  3. Committee meetings
  4. Invitation to participate
  5. Referral
  6. Notes

Documents

Documents created during the development process.

Draft guidance

  • Draft guidance

  • Draft guidance (online commenting)

  • Draft guidance (downloadable version) (PDF 302 KB)

    Published:
    09 June 2026
  • Equality impact assessment (downloadable version) (PDF 127 KB)

    Published:
    09 June 2026
  • Committee papers (PDF 9.29 MB)

    Published:
    09 June 2026
  • Public committee slides (PDF 1.63 MB)

    Published:
    09 June 2026

Declaration of interests

  • Register of interests (MSWord 53 KB)

    Published:
    01 June 2026

Committee meetings

  • Committee meeting: 1

Invitation to participate

  • Final stakeholder list (PDF 134 KB)

    Published:
    10 July 2025
  • Equality impact assessment (scoping) (PDF 132 KB)

    Published:
    10 July 2025
  • Final scope (PDF 133 KB)

    Published:
    10 July 2025
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 460 KB)

    Published:
    10 July 2025

Referral

  • Referral

Notes

  • Note

  • A Technical Engagement consultation took place with registered stakeholders. The Committee meeting was delayed to allow more time for this appraisal.

Back to top